Company: Arcera Life Science
Category: Pharmaceuticals
Afonso leads Arcera Life Sciences, established by ADQ in 2023 to consolidate its shareholdings in Acino International, Birgi Mefar Group, and Amoun Pharmaceutical Company, with a footprint reaching patients in more than 120 countries, a portfolio of 2,000 branded medicines across multiple therapeutic areas, and a workforce of over 6,000 employees. In June 2025, AriBio Co. and Arcera’s Acino signed exclusive licensing, commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. Afonso previously held leadership roles at Novartis, including Sandoz, and Performance Health (a PE owned company).